Targeting inflammation: Cohort study of the influence of methotrexate therapy on sideropenic anemia and reduction of inflammatory markers in rheumatoid arthritis patients
Rheumatoid arthritis (RA) is a systemic autoimmune disease that can cause destructive joint disease and progressive disability. The diagnosis of RA is based on laboratory and clinical evidence, which includes the analysis of inflammatory markers, hematological, and biochemical parameters. Fifty patients diagnosed with RA without methotrexate (MTX) therapy and 50 patients with therapy (MTX, 7.5 mg/week; after three months prednisolone 10 mg/day) were included in this study. After six months of therapy, inflammatory biomarkers, hematological, and biochemical parameters were analyzed. Inflammatory biomarkers: sedimentation rate (SE), C-reactive protein (CRP), and anti-cyclic citrullinated peptide (anti-CCP) are significantly lower in the group of patients on therapy compared to patients without MTX therapy. Significant differences were not found for the rheumatoid factor (RF). Significant differences were not found for hematological parameters between the compared groups. Analysis of serum biochemical parameters showed significant differences for aspartate aminotransferase (AST) and iron values. In patients without MTX therapy, the incidence of anemia was recorded in 68%, which is significantly higher than the incidence of 32% in patients with therapy. Prescribed therapy has shown effectiveness in the treatment of RA and reduction of the inflammatory process. The success of the treatment depends on the timely diagnosis of RA. Postponement of therapy and late-detected disease prolongs therapy treatment and often requires a combination of several drugs.
References
1.
Stokes KY, Granger DN. Platelets: a critical link between inflammation and microvascular dysfunction. The Journal of Physiology. 2012;590(5):1023–34.
2.
Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Annals of the Rheumatic Diseases. 2004;63(10):1218–21.
3.
Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: Results of a twenty‐four–week, multicenter, randomized, double‐blind, placebo‐controlled trial. Arthritis & Rheumatism. 2002;46(3):614–24.
4.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis & Rheumatism. 2004;50(4):1051–65.
5.
Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Annals of the Rheumatic Diseases. 2009;68(7):1094–9.
6.
Gutierrez‐Ureña S, Molina JF, García CO, Cuéllar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis & Rheumatism. 1996;39(2):272–6.
7.
Gerards AH. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology. 2003;42(10):1189–96.
8.
Dalrymple JM, Stamp LK, O’Donnell JL, Chapman PT, Zhang M, Barclay ML. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis & Rheumatism. 2008;58(11):3299–308.
9.
Dechanuwong P, Phuan-udom R. Hematological parameters as a predictor of disease remission in patients with rheumatoid arthritis. Annals of Medicine and Surgery. 2021;72:103085.
10.
Ganz T. Anemia of Inflammation. New England Journal of Medicine. 2019;381(12):1148–57.
11.
Kounis NG, Soufras GD, Tsigkas G, Hahalis G. White Blood Cell Counts, Leukocyte Ratios, and Eosinophils as Inflammatory Markers in Patients With Coronary Artery Disease. Clinical and Applied Thrombosis/Hemostasis. 2015;21(2):139–43.
12.
Ruof J, Hülsemann JL, Mittendorf T, Handelmann S, von der Schulenburg JM, Zeidler H, et al. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer’s data sources. Annals of the Rheumatic Diseases. 2003;62(6):544–9.
13.
Talukdar M. A Study on Association between Common Haematological Parameters and Disease Activity in Rheumatoid Arthritis. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH.
14.
Işık M, Şahin H, Hüseyin E. New platelet indices as inflammatory parameters for patients with rheumatoid arthritis. European Journal of Rheumatology. 1(4):144–6.
15.
Tekeoğlu İ, Gürol G, Harman H, Karakeçe E, Çiftçi İH. Overlooked hematological markers of disease activity in rheumatoid arthritis. International Journal of Rheumatic Diseases. 2016;19(11):1078–82.
16.
Chandrashekara S, Rajendran A, Bai Jaganath A, Krishnamurthy R. Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis. Reumatismo. 67(3):109–15.
17.
Kremer JM, Alarcón GS, Lightfoot RW, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for Rheumatoid Arthritis. Arthritis & Rheumatism. 1994;37(3):316–28.
18.
Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, Barascuk N, et al. Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. 2009;14(3):181–202.
19.
Pallinti V, Ganesan N, Anbazhagan M. Serum biochemical markers in rheumatoid arthritis. Indian J Biochem Biophys. 2009;46(4):342–4.
20.
Smith RJ, Davis P, Thomson AB. Serum ferritin levels in anemia of rheumatoid arthritis. J Rheumatol. 1977;4(4):389–92.
21.
Peeters HR, Jongen-Lavrencic M, Raja AN, Ramdin HS, Vreugdenhil G, Breedveld FC, et al. Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset. Annals of the Rheumatic Diseases. 1996;55(3):162–8.
22.
den Broeder AA, van Herwaarden N, van den Bemt BJF. Therapeutic drug monitoring of biologicals in rheumatoid arthritis: a disconnect between beliefs and facts. Current Opinion in Rheumatology. 2018;30(3):266–75.
23.
Dans LF, Tankeh-Torres S, Amante CM. The prevalence of rheumatic diseases in a Filipino urban population: a WHO-ILAR COPCORD Study. World Health Organization. International League of Associations for Rheumatology. Community Oriented Programme for the Control of the Rheumatic Diseases. J Rheumatol. 1997;24(9):1814–9.
24.
Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Research. 6(1).
25.
McInnes IB, Schett G. The Pathogenesis of Rheumatoid Arthritis. New England Journal of Medicine. 2011;365(23):2205–19.
26.
Chaudhari K, Rizvi S, Syed BA. Rheumatoid arthritis: current and future trends. Nature Reviews Drug Discovery. 2016;15(5):305–6.
27.
Cho SK, Kim D, Won S, Lee J, Choi CB, Choe JY, et al. Factors associated with time to diagnosis from symptom onset in patients with early rheumatoid arthritis. The Korean Journal of Internal Medicine. 2019;34(4):910–6.
28.
Moura CS, Abrahamowicz M, Beauchamp ME, Lacaille D, Wang Y, Boire G, et al. Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study. Arthritis Research & Therapy. 17(1).
29.
Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA, et al. Rheumatoid Arthritis: A Brief Overview of the Treatment. Medical Principles and Practice. 2018;27(6):501–7.
30.
Rein P, Mueller RB. Treatment with Biologicals in Rheumatoid Arthritis: An Overview. Rheumatology and Therapy. 2017;4(2):247–61.
Shakeel S, Iffat W, Qamar A, Rehman H, Ghuman F, Butt F, et al. Healthcare Professionals’ Compliance with the Standard Management Guidelines towards the Use of Biological Disease-Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients. International Journal of Environmental Research and Public Health. 19(8):4699.
33.
Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals. Therapeutic Advances in Drug Safety. 2011;2(3):113–28.
34.
Choy EHS, Smith C, Doré CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology. 2005;44(11):1414–21.
35.
Volin MV, Harlow LA, Woods JM, Campbell PL, Amin MA, Tokuhira M, et al. Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicylic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis. Arthritis & Rheumatism. 1999;42(9):1927–35.
36.
Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(3):168–73.
37.
van der Linden MPM, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TWJ, et al. Long‐term impact of delay in assessment of patients with early arthritis. Arthritis & Rheumatism. 2010;62(12):3537–46.
Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology. 2012;51(suppl 6):vi5–9.
40.
Richards BL, Whittle SL, Buchbinder R. Muscle relaxants for pain management in rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2012(1).
41.
Shrivastava AK, Singh HV, Raizada A, Singh SK, Pandey A, Singh N, et al. Inflammatory markers in patients with rheumatoid arthritis. Allergologia et Immunopathologia. 2015;43(1):81–7.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
